Boston Scientific Corporation(BSX)NASDAQ
Company Profile & Information
Company Profile
Business overview, scale, and footprint
Business Overview
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems.
In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Insider Transactions
Open-market activity and option exercises
Insider Activity Summary
Insider trading activity for Boston Scientific Corporation (BSX) over the last 3 months consists of 145 total transactions. Among these, company executives and board members conducted 145 buys (totaling 3,660,455 shares) and 0 sells (totaling 0 shares). This activity resulted in a net change of 3,660,455 shares, reflecting net buying interest with an estimated net acquisitions value of $16.34M.
145 insider transactions found. Showing 10 of 145 transactions.
| Insider Name | Relation to Company | Shares Changed | Price | Transaction Date |
|---|---|---|---|---|
| MORANO SUSAN E. | Director | 2,040 | $0.10 | Aug 25, 2026 |
| HABIGER DAVID C | Director | 2,100 | $0.10 | Aug 5, 2026 |
| HABIGER DAVID C | Director | 1,182 | $0.06 | Aug 4, 2026 |
| MAHONEY MICHAEL F | Chief Executive Officer | 186,240 | $9.00 | Aug 3, 2026 |
| LUDWIG EDWARD J. | Director | 5,000 | $0.23 | Jul 31, 2026 |
| MONSON JONATHAN R | Chief Financial Officer | 2,087 | $N/A | Jul 1, 2026 |
| MAHONEY MICHAEL F | Chief Executive Officer | 386,755 | $N/A | May 28, 2026 |
| HABIGER DAVID C | Director | 4,450 | $0.25 | May 20, 2026 |
| LUDWIG EDWARD J. | Director | 3,580 | $0.20 | May 20, 2026 |
| PEGUS CHERYL | Director | 1,770 | $0.10 | May 20, 2026 |
Explore More Analysis for BSX
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.